60 Degrees Pharmaceuticals updated its investor presentation highlighting ongoing Arakoda clinical programs for babesiosis and commercial targets toward profitability.
Key Highlights:
- Furnished updated investor presentation (Exhibit 99.1) describing strategy, pipeline and financial overview.
- Arakoda sNDA for babesiosis planned earliest April 2027, contingent on ongoing trials and interim analysis.
- Hospitalized babesiosis trial reached 23 of minimum 24 randomized patients; interim analysis trigger before 10/30/26.
- Expanded access and chronic babesiosis studies ongoing; some early expanded-use cases reported as cured.
- Company targets profitability: Q4 2026 noted for commercial growth and overall target reiterated for 2027/2028 timelines.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.